Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. It is not yet known whether
sunitinib is effective in treating non-small cell lung cancer.
PURPOSE: This phase II trial is studying sunitinib to see how well it works when given as
maintenance therapy in treating patients with stage III or stage IV non-small cell lung
cancer which is previously treated with combination chemotherapy.